The report says IPCA's EBITDA grew 21% YoY with margin expansion to 23%, retaining FY27 guidance, and raises TP to INR2,240 maintaining BUY.
Read this note →IPCA Laboratories Limited
NSE IPCALAB BSE 524494 INE571A01038
0 filings · 0 analysed
1,959.70
+2.31%
over 1 month
-
HSIE Results Daily 06 Nov 26 HSIE
The report says IPCA's EBITDA grew 21% YoY with margin expansion to 23%, retaining FY27 guidance, and raises TP to INR2,240 maintaining BUY.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 06 Nov 2026, 06:42 | long | 1,941.80 | 2,240.00 | — | — | open by 2027-11-06 |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 1,938.50 | 2,010.00 | 1,949.60 | 16% | hit |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report expects 11% YoY revenue growth with gross margin expansion supporting EBITDA margin improvement.
Read this note →The report forecasts IPCA Labs EBITDA growth of 21.0% YoY and PAT growth of 21.3% YoY in 2QFY27.
Read this note →The note mentions IPCA Laboratories gained following the US tariff exemption news for pharma products.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief